InsiderClue
← All stocks

NRX Pharmaceuticals, Inc.

NRXP Net buying
CIK 0001719406 #4115 in the set updated 22 Sep 2026
Bought (120 mo)
$6.84M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$2.97M
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$2.97M
14 of 14 sales
Net
+$3.87M
+$3.87M against sales at will

By person

16 insiders · 39 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Javitt Jonathan C
Chairman and Chief Scientist
$5.94M (4)
$400.00K (1)
+$5.54M
14,406,631
$16.86M
—
Javitt Daniel C.
10% owner
—
$1.35M (9)
−$1.35M
23,606,657
$27.62M
+69.0%
Hurvitz Chaim
Director
$535.03K (4)
—
+$535.03K
778,443
$910.78K
—
Besthof Robert
Interim CEO
—
$470.40K (1)
−$470.40K
23,710
$27.74K
—
Daigneault Alessandra
General Counsel & Secretary
—
$442.00K (1)
−$442.00K
31,584
$36.95K
—
Polar Asset Management Partners Inc. entity
10% owner
—
$312.32K (1)
−$312.32K
488,036
$571.00K
−5.7%
ACKERMAN RICHARD
President and CEO
$225.00K (1)
— (1)
+$225.00K
272,500
$318.83K
−84.4%
Willard Stephen H
CHIEF EXECUTIVE OFFICER
$58.50K (1)
—
+$58.50K
50,000
$58.50K
—
VAN VOORHEES SETH
CHIEF FINANCIAL OFFICER
$51.22K (4)
—
+$51.22K
62,714
$73.38K
+282.9%
Flynn Patrick John
Director
$14.66K (5)
—
+$14.66K
439,500
$514.21K
—
Gorovitz Aaron
Director
$11.20K (1)
—
+$11.20K
130,014
$152.12K
+143.8%
BRAC Lending Group LLC entity
10% owner
—
—
—
562,435
$658.05K
−60.7%
Big Rock Partners Sponsor, LLC entity
10% owner
—
—
—
519,315
$607.60K
+4.4%
Troy Daniel
Director
—
—
—
43,093
$50.42K
—
McMaster Herbert Raymond
Director
—
—
—
18,300
$21.41K
—
Glied Sharon
Director
—
—
—
13,168
$15.41K
—

No percentages here. This company's share count has moved by a factor of 3.6 over the window, from 12,094,094 to 43,295,767 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Individual transactions

20
Insider
Date
Role
Action
Shares
Price
Amount
Javitt Jonathan C
17 Dec 2024
Chairman and Chief Scientist
Buy
40,000
$1.17
$46.80K
Hurvitz Chaim
30 Aug 2023
Director
Buy
70,000
$0.29
$20.13K
Gorovitz Aaron
30 Aug 2023
Director
Buy indirect
35,000
$0.32
$11.20K
Javitt Jonathan C
23 Aug 2023
Chief Scientist
Buy
100,000
$0.33
$33.00K
Javitt Jonathan C
22 Aug 2023
Chief Scientist
Buy
200,000
$0.32
$64.40K
VAN VOORHEES SETH
16 Dec 2022
CHIEF FINANCIAL OFFICER
Buy
30,000
$1.10
$33.00K
Willard Stephen H
16 Dec 2022
CHIEF EXECUTIVE OFFICER
Buy
50,000
$1.17
$58.50K
Flynn Patrick John
28 Nov 2022
Director
Buy
1,750
$1.25
$2.19K
Flynn Patrick John
28 Nov 2022
Director
Buy indirect
2,500
$1.24
$3.10K
Flynn Patrick John
28 Nov 2022
Director
Buy indirect
2,500
$1.25
$3.13K
Flynn Patrick John
28 Nov 2022
Director
Buy indirect
2,500
$1.25
$3.13K
Flynn Patrick John
28 Nov 2022
Director
Buy indirect
2,500
$1.25
$3.13K
VAN VOORHEES SETH
25 Nov 2022
CHIEF FINANCIAL OFFICER
Buy indirect
7,021
$1.11
$7.79K
VAN VOORHEES SETH
25 Nov 2022
CHIEF FINANCIAL OFFICER
Buy indirect
600
$1.10
$660.00
VAN VOORHEES SETH
25 Nov 2022
CHIEF FINANCIAL OFFICER
Buy indirect
8,716
$1.12
$9.76K
Hurvitz Chaim
18 Nov 2022
Director
Buy
40,408
$1.10
$44.45K
Hurvitz Chaim
17 Nov 2022
Director
Buy
171,780
$1.08
$185.52K
Hurvitz Chaim
16 Nov 2022
Director
Buy
287,812
$0.99
$284.93K
Javitt Jonathan C
1 Jun 2022
Chief Scientist
Buy
100,000
$58.00
$5.80M
ACKERMAN RICHARD
29 Nov 2017
President and CEO
Buy indirect
22,500
$10.00
$225.00K
Show all 39 transactions →

What was left out

Form 4 filings counted 47
Amendments (4/A) skipped 4
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 14
Transactions with no price 1
Shares from compensation/vesting 34,883,430
Sales filed before the plan box existed 14
History held since 4 Dec 2017